SCHEMBL8204496

SCHEMBL8204496

Clc1ccc2c(c1)C(N1CCN(Cc3ccc4c(c3)OCO4)CC1)=Nc1ccccc1N2

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 12/20 0.77
DRD1 P21728 10/20 0.77
DRD4 P21917 5/20 0.61
DRD3 P35462 3/20 0.61
CHRM1 P11229 3/20 0.61
DRD5 P21918 2/20 0.53
HRH1 P35367 2/20 0.53
HRH3 Q9Y5N1 2/20 0.53
HRH4 Q9H3N8 2/20 0.52
HTR2A P28223 3/20 0.51
HTR1A P08908 3/20 0.51
HTR3E A5X5Y0 2/20 0.51
HTR3B O95264 2/20 0.51
HTR3A P46098 2/20 0.51
HTR3D Q70Z44 2/20 0.51
HTR3C Q8WXA8 2/20 0.51
CYP1A2 P05177 2/20 0.51
CHRM2 P08172 2/20 0.51
CHRM4 P08173 2/20 0.51
CYP3A4 P08684 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8203868 0.94 DRD2 (0.76) DRD2DRD1DRD4DRD3CHRM1
SCHEMBL29623704 0.93 DRD2 (0.90) DRD2DRD1DRD4DRD3CHRM1
SCHEMBL8203911 0.91 DRD2 (0.75) DRD2DRD1DRD4DRD3DRD5
SCHEMBL8196479 0.89 DRD2 (0.69) DRD2DRD1DRD4DRD3CHRM1
SCHEMBL8204077 0.86 CHRM1 (0.64) DRD2DRD1DRD4DRD3CHRM1
SCHEMBL8202579 0.86 DRD2 (0.61) DRD2DRD1DRD4DRD3CHRM1
SCHEMBL9050759 0.86 DRD2 (0.62) DRD2DRD1DRD3HTR1AHTR3E
SCHEMBL8202569 0.85 DRD1 (0.64) DRD2DRD1DRD3DRD5HRH1
SCHEMBL8203933 0.85 DRD2 (0.74) DRD2DRD1DRD4DRD3CHRM1
SCHEMBL8994839 0.82 DRD2 (0.67) DRD2DRD1DRD4DRD3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6103715-A COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-08-15 US disclosed
US-5538965-A TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-07-23 US disclosed